CSF-1 eye drops show promise in treating presbyopia

Data presented at ASCRS 2023 suggests that CSF-1 (0.4% pilocarpine HCl ophthalmic solution) could be an effective treatment for presbyopia. The Phase 3 clinical trials, NEAR-1 and NEAR-2, which evaluated the safety and efficacy of CSF-1 in treating presbyopia, enrolled 613 participants between the ages of 45-64 years old with...